954124-21-1Relevant articles and documents
Novel 4-phenylpiperidine-2,6-dione derivatives. Ligands for α1-adrenoceptor subtypes
Romeo, Giuseppe,Materia, Luisa,Modica, Maria N.,Pittalà, Valeria,Salerno, Loredana,Siracusa, Maria A.,Manetti, Fabrizio,Botta, Maurizio,Minneman, Kenneth P.
experimental part, p. 2676 - 2690 (2011/07/08)
A number of new 4-phenylpiperidine-2,6-diones bearing at the 1-position an ω-[4-(substituted phenyl)piperazin-1-yl]alkyl moiety were designed and synthesized as ligands for the α1-adrenergic receptor (α1-AR) subtypes. Some synthesized compounds, tested in binding assays for the human cloned α1A-, α1B-, and α1D-AR subtypes, displayed affinities in the nanomolar range. Highest affinity values were found in derivatives having a butyl connecting chain between the 4-phenylpiperidine-2,6-dione and the phenylpiperazinyl moieties. 1-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]-4-phenylpiperidine-2,6- dione (34) showed the best affinity for the α1A-AR (pKi= 8.74) and 10-fold selectivity compared to the other two α1-AR subtypes. Some representative compounds were also tested in order to evaluate their effects on the signal transduction pathway coupled to α1-AR subtypes. They all blocked norepinephrine-induced stimulation of inositol phospholipid hydrolysis, thus behaving as antagonists. Binding data were used to refine a previously developed pharmacophoric model for α1D-ARs. The revised model shows a highly predictive power and could be useful for the future design of high affinity α1D-AR ligands.
Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors
Wilson, Kenneth J.,Illig, Carl R.,Chen, Jinsheng,Wall, Mark J.,Ballentine, Shelley K.,Desjarlais, Renee L.,Chen, Yanmin,Schubert, Carsten,Donatelli, Robert,Petrounia, Ioanna,Crysler, Carl S.,Molloy, Christopher J.,Chaikin, Margery A.,Manthey, Carl L.,Player, Mark R.,Tomczuk, Bruce E.,Meegalla, Sanath K.
scheme or table, p. 3925 - 3929 (2010/09/03)
During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead ary
INHIBITORS OF C-FMS KINASE
-
Page/Page column 24, (2008/06/13)
The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, es